- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00239369
Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5
A Prospective Randomised Study to Compare a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 25 mg With a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg in Patients With Uncontrolled Hypertension Who Fail to Respond Adequately to Treatment With a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Adult patients with high blood pressure who are currently taking one, two or three blood pressure treatments will be asked to take part in the study. It is expected that about 1,600 patients in seventeen countries will enter the screening part of the study and approximately 480 of these patients will be allocated to double-blind randomised study treatment. The study will last for approximately fifteen weeks. Patients will visit the study doctor five times for assessment. After informed consent, patients will start a screening period for four to ten days. During the screening period, patients must take their usual blood pressure treatment but will stop this by the date of the next visit. If the patient is suitable for this study, they will then start run-in treatment period with telmisartan 80 mg plus hydrochlorothiazide 12.5 mg (T80/H12.5) taken as a single tablet once per day for approximately six weeks.
At the end of the run-in treatment period, if the diastolic blood pressure (DBP) is below 90 mmHg, the patient will not proceed as their blood pressure is already controlled by T80/H12.5. If the DBP is 90 mmHg or greater they will start the randomised study treatment period and be randomly allocated to double-blind treatment with either telmisartan 80 mg plus hydrochlorothiazide 25 mg(T80/H25) or T80/H12.5 taken as a single tablet once per day for eight weeks. They will also receive a placebo tablet (a dummy tablet which contains no active ingredient) every day.
They will visit the clinic four weeks and eight weeks later for assessment of their blood pressure and general health. Their participation in the study is complete eight weeks after the start of the randomised treatment period.
Study Hypothesis:
The trial hypothesis is that the reduction in seated trough DBP (i.e., seated trough DBP at the end of the randomised treatment period compared with the seated trough DBP at the start of the randomised treatment period) will be greater in the T80/H25 group compared with the T80/H12.5 group.
Comparison(s):
The efficacy and safety of the two trial treatments (T80/H25 versus T80/H12.5) will be compared. Trough blood pressure is the blood pressure 24 hours after the last dose of trial medication.
Tipo de estudio
Inscripción
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Ellefeld, Alemania, 08236
- Boehringer Ingelheim Investigational Site
-
Florsheim, Alemania, 65439
- Boehringer Ingelheim Investigational Site
-
Frankfurt/Main, Alemania, 60323
- Boehringer Ingelheim Investigational Site
-
Haag, Alemania, 83527
- Boehringer Ingelheim Investigational Site
-
Ingelheim, Alemania, 55218
- Boehringer Ingelheim Investigational Site
-
Nurnberg, Alemania, 90402
- Boehringer Ingelheim Investigational Site
-
Rodgau-Dudenhofen, Alemania, 63110
- Boehringer Ingelheim Investigational Site
-
Unterschneidheim, Alemania, 73485
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Incheon, Corea, república de, 405760
- Boehringer Ingelheim Investigational Site
-
Seoul, Corea, república de, 134701
- Boehringer Ingelheim Investigational Site
-
Seoul, Corea, república de, 152703
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Birker?d, Dinamarca, 3460
- Boehringer Ingelheim Investigational Site
-
Haderslev, Dinamarca, DK-6100
- Boehringer Ingelheim Investigational Site
-
Odder, Dinamarca, DK-8300
- Boehringer Ingelheim Investigational Site
-
R?dovre, Dinamarca, DK-2610
- Boehringer Ingelheim Investigational Site
-
Vildbjerg, Dinamarca, DK-7480
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Badalona / Barcelona, España, 08911
- Hospital Municipal de Badalona
-
Galdakao / Vizcaya, España, 48680
- Hospital de Galdakao
-
Jerez De La Frontera / Cadiz, España, 11407
- Hospital Gral. Jerez de la Frontera
-
L'Hospitalet De Llobregat / Barcelona, España, 08902
- C.A.P. Mosen Cinto Verdaguer
-
Madrid, España, 28007
- Hospital Universitario Gregorio Mara?on
-
Mataro (Barcelona), España, 08303
- C.A.P. Ronda Cerdanya
-
Mostoles / Madrid, España, 28935
- Hospital General de Mostoles - Medicina Interna
-
Santiago de Compostela, España, 15706
- Hospital del Conxo
-
-
-
-
-
Helsinki, Finlandia, FI-00500
- Boehringer Ingelheim Investigational Site
-
Joensuu, Finlandia, FI-80100
- Boehringer Ingelheim Investigational Site
-
Kokkola, Finlandia, FI-67200
- Boehringer Ingelheim Investigational Site
-
Turku, Finlandia, FI-20100
- Boehringer Ingelheim Investigational Site
-
Turku, Finlandia, FI-20520
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Angers, Francia, 49000
- ALTI
-
Angers, Francia, 49100
- ALTI
-
Bobigny, Francia, 93000
- Hôpital Avicenne
-
Paris, Francia, 75015
- Mg Recherches
-
-
-
-
-
Hong Kong, Hong Kong
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Birr, Irlanda
- Boehringer Ingelheim Investigational Site
-
Carrigallen, Irlanda
- Boehringer Ingelheim Investigational Site
-
Dublin 18, Irlanda
- Boehringer Ingelheim Investigational Site
-
Dublin 24, Irlanda
- Boehringer Ingelheim Investigational Site
-
Dublin 9, Irlanda
- Boehringer Ingelheim Investigational Site
-
Enniscorthy,, Irlanda
- Boehringer Ingelheim Investigational Site
-
Gorey, Irlanda
- Boehringer Ingelheim Investigational Site
-
Mallow, Irlanda
- Boehringer Ingelheim Investigational Site
-
New Ross, Irlanda
- Boehringer Ingelheim Investigational Site
-
Toomevara, Irlanda
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Broni (PV), Italia, 27043
- Ospedale Arnaboldi
-
Ferrara, Italia, 44100
- Azienda Ospedaliera Universita di Ferrara
-
Roma, Italia, 00163
- IRCCS San Raffaele
-
Vittorio Veneto (TV), Italia, 31029
- Ospedale Civile
-
-
-
-
-
Kuching, Sarawak, Malasia, 93586
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Elverum, Noruega, N-2408
- Boehringer Ingelheim Investigational Site
-
Moelv, Noruega, N-2391
- Boehringer Ingelheim Investigational Site
-
Oslo, Noruega, N-0369
- Boehringer Ingelheim Investigational Site
-
Skedsmokorset, Noruega, N-2020
- Boehringer Ingelheim Investigational Site
-
Tolvsr?d, Noruega, N-3153
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bennebroek, Países Bajos, 2121 BB
- Boehringer Ingelheim Investigational Site
-
Ewijk, Países Bajos, 6644 CL
- Boehringer Ingelheim Investigational Site
-
Helmond, Países Bajos, 5704 CM
- Boehringer Ingelheim Investigational Site
-
Hoogwoud, Países Bajos, 1817 BG
- Boehringer Ingelheim Investigational Site
-
Nijverdal, Países Bajos, 7442 LS
- Boehringer Ingelheim Investigational Site
-
Oude Pekela, Países Bajos, 9665 BJ
- Boehringer Ingelheim Investigational Site
-
Oude Pekela, Países Bajos, 9665 AR
- Boehringer Ingelheim Investigational Site
-
Rijswijk, Países Bajos, 2281 AK
- Boehringer Ingelheim Investigational Site
-
Roelofarendsveen, Países Bajos, 2371 RB
- Boehringer Ingelheim Investigational Site
-
Rotterdam, Países Bajos, 3082 DC
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bellville, Sudáfrica, 7531
- Boehringer Ingelheim Investigational Site
-
Durban, Sudáfrica, 4091
- Boehringer Ingelheim Investigational Site
-
Johannesburg, Sudáfrica, 2001
- Boehringer Ingelheim Investigational Site
-
Johannesburg, Sudáfrica, 2013
- Boehringer Ingelheim Investigational Site
-
Lenasia, Sudáfrica, 2033
- Boehringer Ingelheim Investigational Site
-
Lenasia South, Sudáfrica, 2033
- Boehringer Ingelheim Investigational Site
-
Midrand, Sudáfrica, 1685
- Boehringer Ingelheim Investigational Site
-
Pretoria, Sudáfrica, 0038
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Eksjo, Suecia, 575 36
- Boehringer Ingelheim Investigational Site
-
Karlstad, Suecia, 651 85
- Boehringer Ingelheim Investigational Site
-
Karlstad, Suecia, 652 24
- Boehringer Ingelheim Investigational Site
-
Uddevalla, Suecia, 451 40
- Boehringer Ingelheim Investigational Site
-
Uppsala, Suecia, 751 25
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Basel, Suiza, 4031
- Boehringer Ingelheim Investigational Site
-
Basel, Suiza, 4051
- Boehringer Ingelheim Investigational Site
-
Basel, Suiza, 4052
- Boehringer Ingelheim Investigational Site
-
Bellinzona, Suiza, 6500
- Boehringer Ingelheim Investigational Site
-
St. Imier, Suiza, 2610
- Boehringer Ingelheim Investigational Site
-
Vezia, Suiza, 6943
- Boehringer Ingelheim Investigational Site
-
-
-
-
-
Taipei, Taiwán
- Boehringer Ingelheim Investigational Site
-
Taipei, Taiwán, 112
- Boehringer Ingelheim Investigational Site
-
Taipei, Taiwán, 104
- Boehringer Ingelheim Investigational Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria:
- Essential hypertension.
- Currently taking between one and three antihypertensive medications at a stable dose for at least four weeks before Visit 1.
- Blood pressure not adequately controlled on existing treatment before entry (inadequate control defined as seated DBP >= 95 mmHg on one current antihypertensive medication or DBP >= 90 mmHg on two or more current antihypertensive medication(s).
- Failure to respond to six weeks treatment with T80/H12.5. (Failure to respond defined as seated DBP >= 90 mmHg at six weeks. This criterion will be assessed at Visit 3.)
- Willing and able to provide written informed consent.
Exclusion criteria:
- Women of child-bearing potential NOT practising acceptable means of birth control, positive serum pregnancy test, breastfeeding.
- Known or suspected secondary hypertension.
- Mean SBP >= 200 mmHg.
- Severe hepatic or renal impairment.
- Bilateral renal artery stenosis (or in a solitary kidney), post-renal transplant or only one functioning kidney.
- Clinically relevant hypokalaemia or hyperkalaemia.
- Uncorrected volume or sodium depletion, primary aldosteronism.
- Hereditary fructose intolerance.
- Previous symptoms of angioedema after ACE inhibitors or angiotensin-II receptor antagonists.
- Drug or alcohol dependency within the previous six months.
- Administration of any medication known to affect blood pressure.
- Concurrent participation in another clinical trial or any investigational therapy.
- Hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve.
- Allergic hypersensitivity to any component of the formulations under investigation.
- Concomitant therapy with lithium, cholestyramine or colestipol resins. non-compliance with study medication (less than 80% or more than 120%) during th e run-in treatment period.
- Any other clinical condition which, in the opinion of the investigator, would not allow safe administration of telmisartan or hydrochlorothiazide.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Change from baseline in trough seated DBP
Periodo de tiempo: 8 weeks
|
8 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Change from baseline in trough seated SBP
Periodo de tiempo: 8 weeks
|
8 weeks
|
Change from baseline in trough standing DBP and SBP
Periodo de tiempo: 8 weeks
|
8 weeks
|
The proportion of patients achieving DBP control (trough seated DBP<90 mmHg).
Periodo de tiempo: 8 weeks
|
8 weeks
|
The proportion of patients achieving DBP response (trough seated DBP<90 mmHg or trough seated DBP reduction from baseline ≥10 mmHg).
Periodo de tiempo: 8 weeks
|
8 weeks
|
The proportion of patients achieving SBP response (trough seated SBP<140 mmHg or trough seated SBP reduction from baseline ≥10 mmHg).
Periodo de tiempo: 8 weeks
|
8 weeks
|
The proportion of patients achieving SBP response (trough seated SBP<140 mmHg or trough seated SBP reduction from baseline ≥20 mmHg)
Periodo de tiempo: 8 weeks
|
8 weeks
|
The proportion of patients in trough seated BP categories: opt.: SBP<120 mmHg and DBP<80 mmHg., norm.: SBP<130 mmHg and DBP<85 mmHg and not optimal, high-normal: SBP<140 mmHg and DBP<90 mmHg and not optimal or normal, high: SBP ≥140 mmHg or DBP ≥90 mmHg
Periodo de tiempo: 8 weeks
|
8 weeks
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades cardiovasculares
- Enfermedades Vasculares
- Hipertensión
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antihipertensivos
- Agentes natriuréticos
- Moduladores de transporte de membrana
- Diuréticos
- Bloqueadores del receptor de angiotensina II tipo 1
- Antagonistas de los receptores de angiotensina
- Inhibidores del simportador de cloruro de sodio
- Hidroclorotiazida
- Telmisartán
Otros números de identificación del estudio
- 502.480
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Fixed dose combination telmisartan 80 mg + HCTZ 25 mg
-
Janssen Research & Development, LLCTerminado
-
Regeneron PharmaceuticalsTerminadoGota intercríticaEstados Unidos, Canadá
-
Yuhan CorporationTerminado
-
Boehringer IngelheimTerminado
-
Merck Sharp & Dohme LLCPfizerTerminadoHipertensión | Diabetes Mellitus, Tipo 2
-
Boehringer IngelheimTerminado
-
Boehringer IngelheimTerminado
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Terminado
-
Vanderbilt University Medical CenterTerminadoTrastornos del metabolismo de la glucosa | Enfermedades metabólicas | Diabetes mellitus | Enfermedades del sistema endocrinoEstados Unidos
-
Daiichi Sankyo, Inc.Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyTerminadoHipertensión esencialBélgica, Alemania, Países Bajos, Eslovaquia